In non-small cell lung carcinoma (NSCLC), a phase II trial of pembrolizumab and stereotactic body radiotherapy doubled overall response rate compared to ICI alone, mainly in PDL-1 negative tumors; suggesting radiotherapy may activate non inflamed tumors to an inflamed microenvironment responsive to ICI (17). This evidence concerns the gene CD274 and non-small cell lung carcinoma.